Enlivex Therapeutics Ltd. Ordinary Shares (ENLV)
Enlivex Therapeutics Ltd. is a clinical-stage biotech company specializing in the development of immune rebalancing immunotherapies for the treatment of severe inflammatory and immune-related conditions. Their flagship product pipeline focuses on harnessing the body's immune system to improve outcomes in conditions such as sepsis, graft-versus-host disease, and other immune dysregulation disorders.
Company News
Enlivex Therapeutics reported positive Phase I/II trial results for Allocetra, showing significant pain reduction and functional improvement in knee osteoarthritis patients, with a favorable safety profile.
Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup cut the price target for Starbucks Corporation (NASDAQ: SBUX) from $102 to $95. Citigroup analyst Jon Tower maintained a Neutral rating. Starbucks shares fell 0.1% to close at $85.90 on Thursday. See how other analysts view this stock. Citigroup slashed the price target for Tesla, Inc. (NASDAQ: TSLA) from $196 to $180. Citigroup analyst Itay Michaeli maintained a Neutral rating. Tesla shares gained 1.7% to close at $174.60 on Thursday. See how other analysts view this stock. Needham cut CarMax, Inc. (NYSE: KMX) price target from $99 to $91. Needham analyst Chris Pierce maintained a Buy rating. CarMax shares fell 9.2% to close at $71.98 on Thursday. See how other analysts view this stock. Mizuho cut the price target for Phillips 66 (NYSE: Full story available on Benzinga.com